FY2026 Earnings Estimate for BNTC Issued By HC Wainwright

Benitec Biopharma Limited (NASDAQ:BNTC) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for Benitec Biopharma in a research report issued on Tuesday, November 4th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings per share of ($1.65) for the year. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.18).

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen raised Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Citigroup reiterated an “outperform” rating on shares of Benitec Biopharma in a research report on Tuesday. Citizens Jmp boosted their price objective on Benitec Biopharma from $20.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Tuesday. JMP Securities set a $22.00 target price on Benitec Biopharma in a research note on Tuesday. Finally, Zacks Research lowered Benitec Biopharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.83.

Benitec Biopharma Trading Down 24.0%

Shares of NASDAQ:BNTC opened at $12.00 on Thursday. The company has a 50 day moving average of $14.52 and a 200-day moving average of $13.78. The company has a current ratio of 54.67, a quick ratio of 54.67 and a debt-to-equity ratio of 0.01. The firm has a market cap of $315 million, a P/E ratio of -8.16 and a beta of 0.23. Benitec Biopharma has a twelve month low of $9.10 and a twelve month high of $17.15.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. MYDA Advisors LLC lifted its holdings in shares of Benitec Biopharma by 4.0% during the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after purchasing an additional 2,000 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Benitec Biopharma during the 2nd quarter worth about $38,000. Bank of America Corp DE lifted its stake in Benitec Biopharma by 2,255.8% during the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,587 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Benitec Biopharma in the second quarter worth about $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Benitec Biopharma in the second quarter worth approximately $93,000. 52.19% of the stock is owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.